drugset / Trial / NCT00639457

Exercise and Pioglitazone for HIV-Metabolic Syndromes

NCT00639457

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose is to examine the safety and efficacy of 16wks of pioglitazone (Actos; 30mg/d) with and without aerobic and strength exercise training for reducing glucose intolerance and central adiposity in HIV-infected people. We anticipate that pioglitazone + exercise training will improve glucose metabolism and insulin sensitivity, and reduce central adiposity more than pioglitazone alone. These improvements should translate into reduced cardiovascular disease risk in HIV-infected people.

Timeline

Start
2005-01
Primary completion
2008-12
Completion
2009-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule 30 mg Oral